|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
EMBRYONIC STEM CELLS |
1 Department of Molecular Medicine and Surgery, Division of Cardiothoracic Surgery and Anaesthesiology, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
2 Department of Medicine, Division of Cardiology, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
3 Department of Clinical Immunology, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
4 Department of Gynaecology, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
5 Department of Nephrology and Transplantation, Lund University, Lund, Sweden
6 Department of Heart Diseases, Cardiothoracic Surgery, Haukelands University Hospital, Bergen, Norway
* To whom correspondence should be addressed. E-mail: karl-henrik.grinnemo{at}karolinska.se.
| Abstract |
|---|
In order to study the ability of costimulation blockade to induce tolerance to human embryonic stem cells (HESC), SCID and immunocompetent C57BL/6 mice treated with costimulation blockade received intra-testicular and intra-myocardial HESC transplants. All SCID mice with intra-testicular HESC transplants developed teratoma. When SCID mice were transplanted intra-myocardially, only two of five mice developed teratoma-like tumors. C57BL/6 mice transplanted intra-testicularly and treated with costimulation blockade all developed teratoma and were surrounded by CD4+CD25+Foxp3+ T cells, while isotype control treated recipients rejected their grafts. Most C57BL/6 mice transplanted intra-myocardially and treated with costimulation blockade demonstrated lymphocytic infiltrates one month after transplantation where as one maintained its graft. Isolation of regulatory T- cells from intra-myocardial transplanted recipients treated with costimulation blockade demonstrated specificity towards undifferentiated HESC and down-regulated naive T-cell activation towards HESC. These results demonstrate that costimulation blockade is sufficiently robust to induce tolerance to HESC in the immune-privileged environment of the testis. HESC specific regulatory T-cells developed to HESC transplanted to the heart and the success of transplantation was similar to that seen in SCID mice.
______________________________________________________________________________
Author contributions: K.G.: Conception and design, administrative support, provision of study material, collection and assembly of data, data analysis and interpretation, manuscript writing and final approval of manuscript; R.G.: Conception and design, administrative support, collection and assembly of data and manuscript writing; M.K.: Conception and design, collection and assembly of data, data analysis and interpretation, and manuscript writing; A.A.: Collection and assembly of data, data analysis and interpretation; C.D.: Conception and design, collection and assembly of data, data analysis and interpretation, and manuscript writing; A.M.: Collection and assembly of data, data analysis and interpretation; G.D.: Conception and design, administrative support, manuscript writing, final approval of manuscript and financial support; A.S.: Provision of study material; H.E.: Financial support and final approval of manuscript; O.H.: Administrative support, provision of study material, manuscript writing and final approval of manuscript; C.S.: Conception and design, administrative support, financial support, manuscript writing and final approval of manuscript; M.C.: Conception and design, data analysis and interpretation, financial support, manuscript writing and final approval of manuscript.
Key Words. Human embryonic stem cells, Foxp3+ T- cells, tolerance, CTLA4Ig, anti-CD40L, anti-LFA-1
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| STEM CELLS | THE ONCOLOGIST | CME | ALPHAMED PRESS JOURNALS |
